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Bcl-2 Related Ovarian Killer, Bok, is Cell Cycle Regulated and Sensitizes to
Stress-Induced Apoptosis
José M. Rodríguez
ABSTRACT
Bok/Mtd (Bcl-2-related ovarian killer/Matador) is considered a pro-apoptotic
member of the Bcl-2 family. Though identified in 1997, little is known about its
biological role. We have previously demonstrated that Bok mRNA is upregulated
following E2F1 over-expression. In the current work, we demonstrate that Bok RNA is
low in quiescent cells and rises upon serum stimulation. To determine the mechanism
underlying this regulation, we cloned and characterized the mouse Bok promoter. We
find that the mouse promoter contains a conserved E2F binding site (-43 to –49) and that
a Bok promoter-driven luciferase reporter is activated by serum stimulation dependent on
this site. Chromatin immunoprecipitation assays demonstrate that endogenous E2F1 and
E2F3 associate with the Bok promoter in vivo. Surprisingly, we find that H1299 cells can
stably express high levels of exogenous Bok. However, these cells are highly sensitive to
chemotherapeutic drug treatment. Taken together these results demonstrate that Bok
represents a cell cycle-regulated pro-apoptotic member of the Bcl-2 family, which may
predispose growing cells to chemotherapeutic treatment.

v

Chapter 1: Introduction

E2F Family of Transcription Factors
The E2F family of transcription factors has key roles in regulating the G1/S
transition 67,79,85,90. There are nine E2F members identified, so far 12,20,24,42,62,89,114,132.
This family can be divided into three distinct groups based on both structure and
function. E2F1, 2 and 3A make up the first distinct group. Structurally, a long N-terminal
region, of unclear function, distinguishes these E2Fs (Fig 1). They also contain a cyclin A
binding domain important for their down regulation in S phase 72,76,144. At the C-terminus,
each possesses a potent transcriptional activation domain that contains an Rb binding
motif 1,44,69,78,78. Functionally, these E2Fs appear necessary for cell cycle progression
1,57,90

, they are primarily expressed at the G1/S boundary 1,27,52,59,65,79,92,116 and they

potently drive S phase when expressed in otherwise quiescent rodent fibroblast 22,67,75,85.

In contrast, members of the second group of E2Fs (3B, 4 and 5) lack the Nterminal region (Fig 1) and are expressed ubiquitously through the cell cycle 134. They
can activate transcription of G1/S genes when over expressed in rodent fibroblast,
particularly E2F3B 43, but do so less efficiently than E2F1-3A 22,85. These E2Fs appear
essential to maintain growth arrest 31,109 and contribute to differentiation 103,109.
Mechanistically these E2Fs may primarily serve to tether Rb to E2F-regulated promoters
1
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Figure 1. Schematic representation of the E2F family of proteins.
Shaded boxes indicate important and conserved domains. What all E2F’s
have in common is the DNA binding domain. E2F1-3 are the activating
E2F’s, where as E2F3B-8 are implicated in growth repression.
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during G0 31,103, and may also serve to generate an initial pulse of E2F activity that is
subsequently amplified by activating the transcription of the more potent E2F1, 2 and 3A.

Finally, E2F6, 7 and 8 represent the third group (Fig 1). These E2Fs appear to
lack the transcriptional activation/Rb binding domain present in other E2Fs and serve
exclusively to repress transcription via interaction with transcriptional repressors
12,20,24,83,89,97,132

. For example, E2F6 binds to transcriptional co-repressors due to its ability

to bind polycomb protein molecules and generally serves to repress growth 97.

E2F Role in Cell Cycle
Progression through the cell cycle is regulated by many proteins, which include
cyclins, cyclin dependent kinases (CDK), cyclin dependent kinase inhibitors (CKI), E2F
family members and the retinoblastoma protein (pRb) family members among others
2,6,9,14,23,32,36,41,45,66,71,73,95,98,106,115,120,121,124,127,128,131,133,146,147

. In a resting cell,

hypophosphorylated pRb and its family members p107 and p130, bind and inactivate the
E2F transcription factors forming the checkpoint during the G1/S boundary. This
checkpoint regulates the transition between cell proliferation and terminal differentiation.
Studies in mouse fibroblast with deleted pRb, p107 or p130 suggest their important role
in the arrest of the G1 phase of the cell cycle 15. When a cell receives mitogenic signals
by growth factors, cyclins become upregulated and form complexes with CDKs. The
main regulators of the G1/S transition are the D type cyclins and their binding partners
CDK4/6 (Fig 2). After mitotic stimulation, cyclin D/CDK4 and cyclinD/CDK6 complex
hyperphosphorylates pRb family leading to the release and activation of E2F. The E2F
3
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Figure 2. Role of E2F in cell cycle control. After mitogenic stimulation
(top left), cyclin D/CDK 4/6 lays the initial phophorylation on RB.
Cyclin E/CDK 2 then continues to phosphorylate RB and this leads to the
hyperphosphorylation and degradation of RB. Thus, E2F’s are free to
transactivate genes required for DNA synthesis. Once in S phase, cyclin
A/CDK 2 in a negative feedback loop targets E2F’s for degradation.
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transcription factor then mediates cell cycle-dependent expression of genes important for
DNA synthesis such as thymidylate synthase (TS), dihydrofolate reductase (DHFR) and
DNA polimerase α 21. Though in vitro E2F1 can bind DNA as a homodimer, in cells E2F
binds promoters as a heterodimer with a memberof the DP family 104,149,150. Association
with a DP protein significantly increases its sequence-specific binding to its target genes.
After S phase induction Cyclin A/CDK2 down regulates E2F by phosphorylating it and
targeting it for degradation 125 (Fig 2). Down regulation of E2F is important for cell
survival because otherwise the cell would undergo apoptosis. In addition to the regulation
of genes required for cell cycle progression E2Fs also regulate genes involved in growth
arrest, differentiation and apoptosis.

Another layer of regulation involves CKI, which mediated growth arrest through
the inhibition of the phosphorylation of pRB and the stabilization of p53; and are
therefore involved in tumor suppression. The CKIs are grouped in two families, the INK4
and the Cip/Kip family 13,40,117. The first family, the INK4 (inhibitors of cdk4) proteins, is
composed of 4 members and selectively inhibits CDK4 and CDK6. The four INK4
inhibitors are p16INK4a, p15INK4b, p18INK4c and p19INK4d, and they do not bind any other
CDKs. The second family, Cip/Kip inhibitors (CDK interacting protein/Kinase inhibitory
protein) are p21Cip1, p27Kip1 and p57Kip2, and in contrast to the INK4 family, they are not
as selective in their activity, and are able to inhibit cyclin E/CDK2 and cyclin A/CDK2.

5

Role of E2F1 in Apoptosis
The most striking functional difference between E2F family members is the
unique ability of E2F1 to induce apoptosis and our laboratory and others have
demonstrated this role of E2F1 by over-expressing it in tissue culture cells and measuring
apoptosis 1,10,22,28,29,33,50,51,53,58,64,81,82,99,100,105,113,122,123,143. Physiologically, E2F1’s role in
apoptosis is suggested by experiments showing that mice deficient in E2F1 develop
tumors in the reproductive tract, lung and lymphatic system, presumably for the lack of
apoptosis 26,139,148. E2F1 can induce apoptosis by both p53-dependent 1,63,100,112 and p53independent pathway 80,123 (Fig 3).

In tissue culture, over-expression of E2F1 leads to the increase of p53 and
subsequent apoptosis. One of the molecular pathways this is achieved is by the direct
transcriptional activation of p14ARF gene (p19ARF in mouse) by E2F1 5,48,82,129,130.
Accumulation of p14ARF leads to its interaction with the Hdm2 (Mdm2 in mouse) E3
ubiquitin ligase. The binding between p14ARF and Hdm2 inhibits the ability of Hdm2 to
target p53 for degradation. As a net consequence the E2F1 increase in p14ARF levels
leads to stabilization and activation of p53. In addition, E2F1 can lead to the
accumulation of a p53 relative by directly transactivating p73. p73 is a homolog of p53
that regulate the p53 promoter 82,136. p73 transactivates some of the same targets genes as
p53 68,82,119 and also has the ability to induce apoptosis in mouse embryonic fibroblast
that are deficient of p53 61 indicating a tumor control mechanism that runs parallel.
Additionally E2F1 can elevate the activity of the ataxia-telangiectasia-mutated kinase 49
promoter and induces an increase in the ATM mRNA and protein. In turn ATM leads to
6
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Figure 3. E2F1 pathways towards apoptosis. E2F1 is the best inducer
of apoptosis among the E2F family and it does this trough a p53dependent (top lanes), and p53-independent (bottom lanes) pathways.
E2F1 can lead to the stabilization of p53 by transactivating ARF, which
leads to the inhibition of Hdm-2 (a protein that targets p53 for
degradation), or by inducing an ATM-dependent phosphorylation of p53.
In addition, E2F1 can induce apoptosis independently of p53 protein by
directly transactivating apoptotic genes or directly repressing survival
genes.
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the phosphorylation and stabilization of p53 as well as E2F1 (in a positive feedback loop)
in response to genotoxic stress 105.

Many cancer cells evade apoptosis by deregulating or mutating the tumor
suppressor gene p53. Most chemotherapeutic agents work by inducing apoptosis incancer
cells, but in many cancer cells the apoptotic induction of p53 is not functional. In the
other hand E2F1 is not found mutated in human cancers and it can induce apoptosis in a
p53-independent manner 19,47,61. Thus, E2F1 and the apoptotic proteins that it induces are
excellent targets that might be used in cancer chemotherapy.

Figure 3 also highlights the fact that E2F1 can induce apoptosis independent of
p53 by transactivating genes involve apoptosis and repressing genes involved in survival
pathways. Our lab showed in a microarray and Northen blot analysis that E2F1 can
repress the survival genes such as myeloid cell leukemia-1 (Mcl-1), amyloid-β precursor
protein binding protein 2(APP-BP2), programmed cell death 4 (PDCD4), and carnitine
palmitoyltransferace I (CPT-I) 87. On top of that, E2F1 can activate genes involved in the
induction of apoptosis such as Bok, apoptosis protease-activating factor 1 (Apaf-1), and
caspase 7 102,111. Increase E2F1 activity leads to the release of cytochrome C from the
mitochondria to the cytoplasm as a consequence of the action of the aforementioned
genes. Thus, E2F1 can tip the balance between pro-survival and pro-apoptotic genes
towards cell death.

8

Bcl-2 Family of Proteins
Apoptosis or programmed cell death is an important process for the maintenance
of tissue homeostasis and the prevention of diseases such as cancer. A number of targets
in E2F-regulated cell death have been identified and these include members of the Bcl-2
family 19,25,39. The Bcl-2 family of proteins consists of different anti- and pro-apoptotic
members that mediate cytochrome C release from mitochondria and thus play important
roles in the “decision” step of the intrinsic apoptotic pathway 16,108. All members of the
Bcl-2 family are characterized by containing at least one of the four Bcl-2 homology
domain (BH). Traditionally anti-apoptotic members, contain all four BH domains, where
as pro-apoptotic members contain only three or less. Within the pro-apoptotic members
there is a subgroup that contain only one BH domain (the BH3-only members), which is
presume as a critical death domain in the pro-apoptotic 91. Bok, a pro-apoptotic member
of the Bcl-2 family, was first cloned in a yeast two hybrid screen of an ovarian cDNA
library for proteins that interacted with Mcl-1, BHRF1 and Bfl-1 55. The mouse homolog
(Mtd) was identified bioinformatically 60. Bok contains Bcl-2 homology domains (BH1,
2, 3) and can heterodimerize with Mcl-1, BHRF-1 and Bfl-1, but not Bcl-2 or Bcl-xl
54,55,60

. Bok can induce apoptosis in a variety of cell types 7,54,55,60,126 and this activity is

inhibited by Mcl-1, BHRF-1 and Bfl-1, but not Bcl-2 or Bcl-xl. There have been reports
that Bok has a nuclear export signal within its BH3 domain and that Bok localizes to the
nucleus as well as the cytoplasm 4. They also showed that accumulation of Bok in the
nucleus increases Bok’s apoptotic activity. In the present work, we investigated the
transcriptional regulation of Bok and its potential roles in cell cycle. We find that Bok is
an E2F-regulated gene activated by serum stimulation that localizes mainly in the
9

cytoplasm, and that it may function as a checkpoint sensitizing growing cells to stressinduced apoptosis.

Chemotherapeutic Agents
One of the hallmarks of cancer is the limitless replicative potential, which is not
under strict regulatory control as in a normal cell. Cancer cells lose the ability to respond
to contact inhibition. In addition cancer cells bypass cell cycle checkpoints and apoptosis
that otherwise a normal cell will undergo after “sensing” an imbalance or an uncontrolled
regulation of cell division. Most of the chemotherapeutic agents developed target this
characteristic of a rapidly dividing cancer cell. The first chemotherapeutic agent was
discovered by accident during World War I when Mustard gas was used as a chemical
warfare agent. The observation that people that were exposed to this gas had low blood
cell count intrigued scientist and motivated them to study it further. During the decade of
the 1940s, patients with lymphomas were given the drug intravenously (instead of
inhaling the irritating gas) and scientist saw a remarkable improvement, although
temporary 101,137. Thereafter many studies have focus on discovering or developing other
chemical agents to kill rapidly dividing cells such as cancer cells. Most of the
chemotherapeutic agents can be classified as alkalating agents, antimetabolites, kinase
inhibitors or topoisomerase inhibitors. In my research I used the chemotherapeutic agent
Flavopiridol, which is a kinase inhibitor, and VP-16 (a.k.a. etoposide) that is a
topoisomerase II inhibitor because they function via E2F1. We believe that Flavopiridol
inhibits cyclin A/cdk 2’s ability to phosphorylate E2F1 and target it for degradation,
leading to its stabilization and consequent transactivation of apoptotic target genes, where
10

as VP-16 induces cell death by stabilizing topo II-double stranded breaks complex, which
leads to the accumulation of ATM kinase, and subsequent phophorylation and
stabilization of E2F1.

Flavopiridol
Flavopiridol is one of the most studied CDK inhibitors. A semi-synthetic Nmethylpiperidinyl chlorophenyl flavone alkaloid compound originally isolated from the
leaves of Amora rohituka. It was first intended to be used as an inhibitor of EGFR,
however upon examination it was found to inhibit the cell replication CDKs at a far lower
concentration. At nanomolar concentrations, Flavopiridol was shown to inhibit CDK4
and CDK6 11,93, the main kinases known to regulate the G1/S transition and E2F1
activity, among others. Its been shown in clinical trials that combination of Flavopiridol
treatment and other chemotherapeutic drugs, such as docetaxel, can increase apoptosis in
cancer cells 34. Flavopiridol induces cell cycle arrest in G1 in vivo and in vitro 96,107,142. It
is cytotoxic to cells synthesizing DNA and can induce apoptosis in a p53-independent
manner 118. Flavopiridol stabilizes E2F1 protein levels in a dose-dependent manner and
the inverse effect is seen on the Mcl-1 levels 86. One of the proposed mechanisms in
which Flavopiridol can lead to apoptosis is by antagonizing cyclin/cyclin dependent
kinase 2’s ability to target E2F1 for degradation. This leads to E2F1 stabilization and
subsequent reduction in Mcl-1, a pro-survival protein, and presumably the accumulation
of pro-apoptotic E2F1 target genes such as Bok, p73, caspases and others. In this study
we assess the importance of Bok, an E2F1 target gene, in the sensitivity of Flavopiridolinduced apoptosis. We found that higher expression of the Bok protein, the faster the
11

induction of apoptosis by Flavopiridol. This observation suggests that assessing a
patient’s levels of Bok might predict the outcome response of the flavopiridol treatment.

VP-16
Topoisomerase II is a ubiquitously express enzyme that regulates the winding of
DNA 30,77. It removes the knots and tangles generated during DNA replication and
transcription, through the creation of double-stranded breaks in the double helix. VP-16 is
a chemotherapeutic agent that targets topoisomerase II enzyme 3,8,38,84,94,151, and has been
used for several types of cancer including lung, prostate, ovarian and testicular cancer.
VP-16 works by stabilizing a covalent enzyme-cleaved DNA complex. After treatment
with VP-16, cells accumulate enzyme-cleaved DNA complexes, which results in the
generation of permanent DNA strand breaks that in turn trigger recombination/repair
pathways and mutagenesis. The massive accumulation of these breaks can overwhelm the
cell and can trigger the initiation of death pathways. Thus, VP-16 converts topoisomerase
II from an essential enzyme to a potent cellular toxin that fragments the genome.

12

Experimental Procedures
Cloning the Bok promoter- Approximately 5x105 plaques from a Sau3A I
partially digested 129SV mouse genomic library in λFIXII (Stratagene) were screened in
duplicate with a mixture of Bok cDNA probes. The probes consisted of full-length
human Bok cDNA (nt 247-882 of NM_032515) (human and mouse sequences are 88%
identical in the coding region) and a 3’ UTR mouse Bok probe (nt 940-1430 of
NM_016778). Screening was performed in 50% formamide and filters were washed at
high stringency. Ten positive plaques were identified and rescreened in secondary and
tertiary screens using the same combination of probes. Following plaque purification and
a quaternary screen, seven purified positive plaques were identified. Plate lysates were
prepared from these seven clones to serve as phage stocks. The phage stocks were
titered, then used to prepare plate lysates to extract the phage DNA. Phage DNA was
extracted using the Qiagen MIDI lambda kit according to manufacturer’s specifications.
NotI digestion of the phage DNA indicated that each clone had a different sized insert,
each in the ~15-20 kb range.

Each of the phage DNAs was digested with a panel of restriction enzymes, then
loaded on duplicate 0.8% agarose gels. The digested DNA was Southern blotted
overnight to Immobilon Ny+ membranes. The duplicate blots were hybridized to each of
the Bok probes individually to roughly map the 5’ and 3’ ends of the inserts. Comparison
of the hyridization to each of the probes revealed similar, but not identical, patterns of
hybridizing bands. This indicated that the clones were unique.

13

Each of the phage DNAs was then digested with NotI to excise the entire insert
for cloning into pBluescript (pBS). In addition, based on differential hybridization
patterns, phage DNAs was also digested with XhoI or SstI to subclone smaller fragments
into pBS. Bluescript clones containing inserts were sequenced with T3 and T7 promoter
primers using the Moffitt Cancer Center Molecular Biology Core Facility. Sequences
were BLASTed against the mouse genome database to confirm the ends of each clone.
Each clone matched an area of the Mus musculus chromosome 1 genomic contig
NT_039173.2. Overlapping clones covering the entire Bok locus are shown in Figure 1.
Clones 8N1 (approximately 15 kb, 8090408- (the 3’ and has not been determined due to
suboptimal sequencing), 11N6 (16.2 kb, 8083204-8099427) and 15N9 (16.8 kb,
8089917-8106754) contain the entire phage insert. In particular, clone 11N6 contains the
entire Bok coding region and will be used to prepare the targeting construct.

Plasmids-Mouse Bok promoters were generated by digestion of pBS-13S2 with
Sst I and ligated into pGL3 basic. Initial PCR primers were design to amplify 331 bp (244/+87) of our sequenced Bok promoter, which are numbered relative to the
transcriptional start site. The forward (192 F) and reverse (141 R) PCR primers for the
Bok promoter were 5’-GGTACCAGAACTTGTGCTGGCCTTTCT-3’ and 5’AAGCTTAGTTCTGGTTTCAGGACCCGC-3’, respectively. The forward primer added
a Kpn I site, and the reverse added a Hind III site to facilitate sub-cloning. The E2F
binding site mutant of the Bok promoter was generated by site-directed mutagenesis with
PCR. The initial reaction was done using 192 F and 192 R (5’TCCGCCGGTCTTCCATCGCGC-3’); a second reaction used primer 141 F (5’14

CGCGATGGAAGACCGGCGGA-3’) and 141 R. The PCR products from these
reactions, 192 bp and 141 bp respectively, were band purified, phenol/chloroform
extracted and ethanol precipitated. They were then resuspended in water, combined, and
used as template in another PCR reaction using the flanking primers 192 F and 141 R.
The resulting PCR product was inserted in pCRII-TOPO, followed by digestion with Kpn
I and Hind III (to excise PCR insert). Insert was run in a 1% agarose gel and band
purified using QIAquick gel extraction kit (Quiagen) and ligated to pGL3 luciferase
vector. The E2F1 mutant constructs, E2F1 (1-284) and E2F1 (Eco 132) have been
previously described 17,18.

Cell culture- Mouse NIH 3T3 fibroblasts were cultured in Dulbecco’s Modified
Eagles Medium (DMEM) supplemented with 5% calf serum. The H1299 lung cancer cell
line was cultured in DMEM supplemented with 5% fetal bovine serum. H1299 cells that
constitutively express Flag-Bok fusion protein were obtained by transfecting with
pcDNA3-Flag-Bok (a gift from Gabriel Nunez, Univ. of Michigan) and selecting for
transformants in 400 µg/ml G418. G418-resistant lines were screened for expression of
Flag-Bok. Adenoviruses were described previously 18,87 and were tittered by plaque
assay. Cell cycle parameters were measured by fixing cells with 70% ethanol-PBS,
staining with propidium iodide (PI) and analyzing by FACS, using ModFit.

Biochemical assays- Transfections were performed using LipofecAMINE
PLUSTM Reagent from Invitrogen with test DNA totaling 2.85 µg of DNA per 60-mm
dish. Transfections included 100 ng of expression plasmids (pcDNA3-based vectors), 2.5
15

µg of test construct firefly luciferase reporter plasmid (pGL3, Promega), and 250 ng of
renilla luciferase reporter plasmid (pRL-TK, Promega). Cells were harvested 48 hrs after
transfection, and luciferase assays were performed using the Dual-Luciferase Reporter
Assay System following the manufacturer’s protocol (Promega). Experiments were done
in duplicate or triplicates, and the relative activities and standard deviation values were
determined. To control for transfection efficiency, firefly luciferase values were
normalized to the values for renilla luciferase. Western blots were performed as
previously described 18,86 using monoclonal antibody against Flag epitope (F3165,
Sigma) or against PARP antibody (Cell signaling 9542). Western blots were stripped and
re-probed with an antibody to actin (A5441, Sigma) to ensure equivalent loading.

RT-PCR-Isolation of total RNA was done using the RNeasy mini kit (Qiagen
74104) as recommended by manufacturer. Total RNA was primed with random hexamers
and cDNA created using SuperScripTM First Strand Synthesis System for RT-PCR
(Invitrogen 11904-018). PCR primers were designed to amplify 490 bp. The forward and
reverse primers were 5’-CGCTCGCCCACAGACAAGGAG-3’ and 5’TCTGTGCTGACCACACACTTG-3’.

Chromatin Immunoprecipitation- ChIP assays were performed as previously
described 18,37,86,110,138-140. Briefly, asynchronously growing NIH 3T3 cells were treated
with formaldehyde to create protein-DNA cross-links, and the cross-linked chromatin
was then extracted, diluted with ChIP buffer, and sonicated. Sonicated chromatin was
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divided into equal samples for immuno-precipitation. Antibodies used included E2F1 (sc193X), E2F3 (sc-878X), and IgG (sc-2027) (from Santa Cruz Biotechnology).
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Chapter 2: Characterizing the Bok Promoter

Identification of Bok as a Potential E2F1 Target
In a previous microarray screen 87, we identified Bok as a potential E2F1 target
gene. To confirm this observation, we tested if over-expression of E2F1 would correlate
with increased expression of Bok mRNA. NIH 3T3 cells were brought to quiescence by
48-hrs incubation in 0.5% calf serum. Cells were then stimulated with 10% fetal calf
serum or were infected with ten plaque-forming units of the indicated adenovirus per cell.
Fig. 4 highlights the observation that Bok mRNA is very low in quiescent NIH3T3
fibroblasts (lane 3), but is highly induced following infection with an E2F1-expressing
adenovirus (lane 1). Lane 4 reveals that serum treatment, which stimulates quiescent cells
to enter S phase, also elevated Bok message (lane 4), suggesting that Bok is E2F and cell
cycle regulated. As a control we wanted to determine the cell cycle status of the treated
cells (Fig 4) by harvesting half of the samples and fixing the NIH 3T3 cells with 70%
ethanol-PBS, stained with PI and analyzed by FACS. Figure 5 demostrate that NIH 3T3
cells were brought to quiescence by 48-hrs incubation in 0.5% calf serum (accumulation
in G0/G1), and upon stimulation with 10% fetal calf serum or infection with ten plaqueforming units of E2F1 adenovirus, cells progress through the cell cycle, in contrast to
empty-vector control virus.
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Figure 4. Bok mRNA is activated by E2F1 or serum stimulation. NIH
3T3 cells were brought to quiescence by 48-hrs incubation in 0.5% calf
serum. Cells were then stimulated with 20% fetal calf serum or were
infected with ten plaque-forming units of the indicated adenovirus per
cell. Total RNA was harvested after 24 hrs (serum) or 30 hrs (virus).
Twenty microgram of RNA were subjected to Northern analysis using
the indicated cDNA probes.
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Figure 5. Cell cycle status of NIH 3T3. NIH 3T3 cells were brought to
quiescence by 48-hrs incubation in 0.5% calf serum. Cells were then
stimulated with 10% fetal calf serum or were infected with ten plaqueforming units of the indicated adenovirus per cell. Cells were harvested
after 24 hrs (serum) or 30 hrs (virus). NIH 3T3 cells were fixed with 70%
ethanol-PBS, stained with PI and analyzed by FACS.
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The Bok Promoter Contains a Conserved E2F Binding Site Between Mouse and
Human.
To understand how Bok is regulated in an E2F/cell cycle-dependent manner, we
compared the genomic sequences of human (AC110299) and mouse Bok (NT_039173).
To obtain authentic Bok genomic sequence from mouse, we screened a lambda phage
library using a mixture of human cDNA probes and mouse UTR Bok probes. Fig 6 shows
a schematic of the various clones obtained. One of the sub-clones, 13S2, which contains
the first two Bok exons and over 900 bp of upstream promoter region, was sequenced.
Comparison of the mouse and human Bok 5’ regions (shown in Fig. 7) revealed
significant sequence homology within the first exon (non-coding) and in a region –244
upstream of the putative transcriptional start site in mouse 141.

Crude deletion analysis localized the promoter to –244/+87 (not shown).
Potentially important motifs within this region include numerous SP1 binding sites and,
most importantly, a conserved E2F1 consensus-binding site. We used PCR to generate a
luciferase reporter vector using the mouse genomic sequence from –244/+87. To examine
the role of the conserved E2F1 site spanning from position –43 to –49, we also generated
a mutated version of the –244/+87 construct in which the E2F1 site was rendered
nonfunctional. Fig. 8 shows a schematic representation of the constructs generated. They
differ in that the consensus E2F binding site CGCGCGGGAAGACCGGCGGA (wild type) is
changed to CGCGATGGAAGACCGGCGGA (mutant).
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Figure 6. Overlapping subclones in pBS encompassing the entire Bok
genomic locus. (A) Subclones were excised from the phage clones with
Sst I (S), Xho I (X) or Not I (N). Not I subclones represent the entire
insert of the phage clones, whereas Sst I and Xho I subclones contain only
part of the original phage clone. Numbering is relative to the Mus
musculus chromosome 1 genomic contig NT_039173.2, which contains
the Bok locus. Solid boxes indicate exons. Exon 1 is noncoding. The
ATG start codon is located at position 8083483 in exon 2. The stop
codon is located at position 8092198 in exon 5. (B) The pBS-13S2 was
further subcloned into pGL3 luciferase vector using Sst I, Sma I or Xba I.
These subclones contain the Bok promoter region and the longest four
putative E2F binding sites marked by black circles.
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ATCCTATTGTTCAAACTGTGTGAGGTTGATTCAAGGATAAAGAAATAAACCAGTGGGATAGAGTTCCGAG hbok
TTCCTGCAGGTTGGACCAGCT**GGTCAACACAGAGCTCCAGA**CAAGCCTCT***CTCTCTTTGTGAG mBok

(-843/-781)

ACACACACACACACACACACACACTCTTCAGCTGATTTATGTTGAGATGTTGGGGACTCCTCCAATTCGG hbok
TCTCTC*******TGTCTCTGCCTCTCTCTGTGTCTCTGTCTC****TCTCCCTCCCTCCCCTTTTTCTG mBok

(-780/-722)

TGGAAAAAAAATGA**TGCTTTTCAATAAATGATGCCAGGTCAATTGGATATCTACACGAAAAAAAATGA hbok
TCAAAGGGAAATACCCTAATGAGAGATAACTAACTACAAAA*GATTATATATTGGATTGGATATAAATAA mBok

(-721/-653)

GCTCTAGCCCCGTA****CCACACCATTCACAATAATTAATATGTAATCAATCATAG*ATCTAAATATGA hbok
G*TCCAGCTCATTAAAAGCAAAGCTAGACTTGAGTGGGAATGGATGGGTATTTGTAGTATCTTCAACCAT mBok

(-652/-584)

GCCCTAAAACAAGCTTCTAAAAGGAAATACAGGAGGATATCCCAATAAAAAGGTACTAACCATAAAGAAA hbok
GTACATACCCAAGTCTTCACCACACTCCAAAGG*********CTCTATTAAG***CCAAGAATGCAGAAT mBok

(-583/-526)

ATATTGATAAATTGGACATCACTAAGAGTAACTCCTGTTCATCCAAAGCAAAAGTAAACCACAAAATAGA hbok
CTATTTTTAAATAT****TTACTTATTGTTATTTTTGTT**TTGTGTATGAATGTTTGCCT********G mBok

(-525/-470)

GGAAGATATTTGCAATAACTTCAATAAATGCGAATCCAATAATCCATCTACAATACAA*AGGGCATGCG* hbok
CCTCCATGTCTGTG**AATCCCCGTGCATGC****CTGGTG*TCCTTGGAGATCAGAAGAGGGCATCAGA mBok

(-469/-407)

TCCGGACCAAGAACACGTCTCCAGACTCTGGAAAGAACCTCTACGAACGAAGAAGACAACCCAA****** hbok
TCTCCTACAACTTCAAGAATCCAGGATCTTTAAGGAGCCTCTATAAGACAATAAGGAAATATAAGTCAGC mBok

(-406/-337)

***TTTTCAAATGGACCCCGGGGAACACCCAGGCGGCTGGGGCTGGCTCTAGGTCCCCACTGCTCTGCCT hbok
TCATTTTAAAATGGAACTTGGTGCGC*CCCAGTGGGTTGGTGTCAGAGCTGGATGTTCTTCGCGCTGCCT mBok

(-336/-268)

TGCGGGGGCCGCTCCGGCCTGGTCGCCTTCTCCGGGCGCATCCAGGGAACTCGCTC*GGTCCTCCTTAAG hbok
*GCCGGGACAGCTCCAGTCTGGCGGCGTTC*CCGGGCGCATCCCGAGAACTTGTGCTGGCCTTTCTTAAA mBok
Sp1

(-267/-200)

Figure 7. Evolutionary conserved E2F binding site. An alignment
between the mouse (NT_039173) and human (AC110299) Bok gene
sequences using MegAlign (DNASTAR, Inc) showed a conserved
putative E2F binding site that extends from position –42 to –49 relative
to the putative transcriptional start site in the mouse sequence. Shaded
blocks indicate sequence identity of at least five base pairs. Boxed areas
indicate putative transcription factor binding sites identified by
MatInspector (Genomatix). The highlighted G at +1 in the mouse
sequence indicates the putative transcription start site based on NCBI
annotations (1).
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C*GGGGAAGC*TCGGAAAGCGTCT**CCCCGACTCCGCCCCCA*GGGTTGCCTTTCCCTTAGAAGGCCAA hbok
CCAGGGAGGCGTTGGGCAGAGCTGGGCTGCGGCTCCGCCCCCGGGGGTTGCCGTTTCCTTAGAAGGCGAA mBok
Sp1
Myb

(-199/-130)

GCCCCAAGCCCAGCCTCTCGCCAGCTGGGAGTCGCGCGCTGCCCACCTCGCTGCCCAGGCCCCCGACGCC hbok
GCCCTAAGCCTGGCTTCTCGCCCGCGGGGAGAC*CGCGGTACGCCTCCCGC*****AC*CCCTCGGGACC mBok
Sp1

(-129/-67)

GCGGCAGGAGCCCCCCAAGAGCGCGGGAAGCCCCGTGGACCTGGCGCTCCCGGCTCGGGCGTGGACGGGG hbok
*****AGGACTTCTGCGAGCGCGCGGGAAGACCGGCGGAGCCTGTGCTTC*AGCTCGGGTGTGGACGGGG mBok
E2F/Ets1
Sp1
-49
-43
CGGGCGCCGGGGCGGGGCGCGCGTCCTCGCGGGTCTGAATGGAAGGGTCGAGGTCGTCGT***CGGCGGC hbok
CGGGCGCTGGGGCGGGGCGCGCG**CTCGCGGGTTTGAATGGAAGGGTCTAGACCGCCGGAGACGGCAGC mBok
Sp1
Sp1 Sp1
Ets1

(-66 to -3)

(-2 to +66)

+1
GAGCAGATCCTGAAGCCAGAACTCCACCCCGGCGCC*CGCGCCATGCGGCGGGAGA*end exon I
hbok
GAGCGGGTCCTGAAACCAGAACTCCACCGCCGCCCCGCGCGCCATGAGGCGGGAGAGGTGAGTCGGGCGG mBok
Sp1
NF-1
Sp1
Hbok
GCGTGGCGTCGGTGCCCTGGATGT*end exon I
mBok

24

(+67/+136)
(+137/+160)

mBok –244/+87 E2F WT

Luc

mBok –244/+87 E2F MUT

Luc

Figure 8: Schematic representation of the Bok promoter. Sitedirected mutagenesis assay was used to mutate the putative E2F binding
site. The Bok promoter containing wild type (closed circle) or mutated
(X) E2F binding site are shown. These fragments were then cloned into
pGL3.
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Regulation of the Bok Promoter Throughout Cell Cycle
To characterize the activity of the cloned Bok promoter throughout the cell cycle,
NIH 3T3 cells were transfected with Bok –244/+87 WT or MUT promoter/reporter. Cells
were brought to quiescence by incubation with 0.5% calf serum for 48 hrs and were then
serum stimulated with 10% fetal calf serum and harvested every 6 hrs. In parallel, cells
were fixed with 70% ethanol-PBS, stained with PI and analyzed by FACS to determine
cell cycle status. Fig. 9A shows that the activity of the WT Bok promoter is maximal at 6
and 12 hrs after addition of serum corresponding to the mid to late G1 phase of the cell
cycle (Fig 9B). This pattern of regulation is very typical of an E2F1-regulated gene. In
contrast, the activity of the MUT Bok promoter is unaffected by serum addition. This
supports the conclusion that the conserved E2F binding site at -49/ -43 is central to the
cell cycle regulation of Bok.

Activation of the Bok Promoter is Not Specific to E2F1.
E2F1 is the most potent inducer of apoptosis amongst the E2F family of proteins
and appears essential for E2F-induced apoptosis 22,74. Since Bok is a known pro-apoptotic
protein, we anticipated that E2F1 might be a specific activator of Bok. To test this idea,
we compared the ability of various E2Fs to induce the Bok luciferase reporter. We cotransfected the wild type (Bok –244/+87 WT) promoter, or the E2F site mutant (Bok –
244/+87 MUT) in the presence and absence of exogenous E2F proteins (Fig 10A). E2Fs
1, 2 and 3B expression each led to promoter activation. This result suggests that
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Figure 9: The Bok promoter is activated by addition of serum
dependent upon a conserved E2F binding site. (A) NIH 3T3 cell were
transfected with the WT or MUT –244/+87 Bok promoter luciferase
construct and then brought to quiescent by 48-hrs incubation with 0.5%
calf-serum. Following starvation cells were stimulated with 10% fetal
calf serum and harvested every 6-hrs and assayed for luciferase activity.
(B) Cells cycle progression of NIH 3T3 cells after treatment as above.
Cells were fixed with 70% ethanol-PBS, stained with PI and analyzed by
FACS. Luciferase assay was performed three time in triplicates each. p
values were less than 0.05 at 6 and 12 hrs after serum treatment.
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activation of Bok is not specific to E2F1. The growth-repressing members of the E2F
family E2F4, 5 and 6 did not significantly activate the promoter and neither did two E2F1
mutants. E2F11-283 is a C-terminally truncated version of E2F1 18 that does not have a
transcriptional activation domain, indicating that activation of the Bok promoter requires
the activation domain. Likewise, the DNA binding E2F1 mutant, Eco 132 17, was unable
to activate transcription. Thus, DNA binding is required for activation of the Bok
promoter.

Since E2F1 and E2F3B were the most potent activators of the Bok promoter in
the comparison of Fig. 5A, we focused experiments comparing E2F1, E2F3A and
E2F3B. Together Fig. 10A and 10B reveal that E2F3A is the most potent inducer of the
Bok promoter followed by E2F3B, E2F1 and E2F2. Although the importance of this
pattern of activity is not certain, it is clear that E2F1 is unlikely to be the sole regulator of
Bok. The observation that over-expression of E2Fs can stimulate the MUT Bok reporter
suggests that additional functional E2F binding sites may exist in the promoter, if E2F
levels are sufficiently high.

The Bok promoter is Not Activated by p53 Expression.
A recent report suggested that Bok was a p53 target and that Bok was an essential
mediator of p53-mediated apoptosis during treatment with chemotherapuetic drugs 145. In
their study they evaluated the role of caspases and new protein synthesis in the induction
of the intrinsic pathway of apoptosis. They demonstrated that if protein synthesis was
inhibited by treatment of cyclohexamide they would block the induction of apoptosis by
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the DNA damaging agent VP-16. They also demonstrated that the activity of the tumor
suppressor p53 was also necessary for apoptosis induction by VP-16. They then
investigated what pro-apoptotic members of the Bcl-2 family were up-regulated by VP16, in which Bok and Noxa were identified. Furthermore, experiments with RNAi
targeting exogenous Bok ans Noxa demonstrated their importance in the apoptosis
induction after VP-16 treatment. Taken together their results suggested that p53 activity
and new protein synthesis was required for apoptosis induction after DNA damage by
VP-16 and that decreasing the expression of exogenous Bok and Noxa significantly
protected from cell death after VP-16 treatment. In their discussion they strongly
suggested the possibility of p53 elements on the promoter of Bok and Noxa that would
account for the activation of these proteins. However, sequence analysis did not reveal a
p53 element in the Bok promoter, calling to question whether Bok is indeed a direct p53
target. To test this, we cotransfected NIH 3T3 cells with our –244/+87 WT Bok construct
in the presence or absence of p53 expression (Fig 11A). In this experiment we can
conclude that E2F1 is a stronger inducer of the Bok promoter than p53. However, we do
not exclude the possibility of other p53 binding sites further upstream or downstream of
the E2F binding site that are not present in our Bok promoter construct (-244/+87). In
addition, we are also limited by our control, a p53-regulated reporter that was induced
two-fold under identical conditions, similar to the induction of the Bok promoter (Fig
11B). Future experiments with larger Bok promoter constructs and additional controls
such as a Bax promoter construct could proof or disproof the hypothesis that the Bok
promoter is regulated by the tumor suppressor p53.

29

Relative promoter activity

A

8

pcDNA3
E2F1

7

E2F2
E2F3B

6
5

E2F4
E2F5

4

E2F6

3

E2F1 1-283
E2F1 Eco 132

2
1
0

WT

MUT
mBok –244/+87

B

Relative promoter activity

9

pcDNA3

8

E2F1

7

E2F3A

6

E2F3B

5
4
3
2
1
0

WT

MUT

mBok –244/+87

Figure 10: S phase promoting members of the E2F family activate
the Bok promoter. (A) E2F binding site MUT and WT Bok promoters
were co-transfected with expression vectors for different members of the
E2F family and their ability to activate the Bok promoter was measured.
(B) Same as in A except focusing on strongest S phase promoting E2Fs.
E2F3A is the most potent activator of the Bok promoter. Experiments
were performed in twice in triplicates each. p values were less than 0.05
for E2F-1, -2, -3a and -3b.
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Figure 11. p53 protein does not activate the Bok promoter. (A) E2F
binding site MUT and WT Bok promoters were co-transfected with either
E2F1 expression vector or p53 expression vector and measure their
ability to activate the Bok promoter. (B) As a control p53 was coexpressed with a known p53 regulated promoter, BP100. Experiment was
performed twice in triplicates each. p values were less than 0.05.
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E2F1 and E2F3 Associate With the Bok Promoter in vivo.
In light of the fact that E2F1 and E2F3A potently activate the Bok promoter in
context of a luciferase reporter, we wanted to determine whether E2Fs associate with the
Bok promoter in vivo. For this, we turned to chromatin immunoprecipitation assay of
asynchronous NIH 3T3 cells. As shown in Fig. 12, using Bok specific oligonucleotide
primers that span –244 to +87 of the murine Bok gene, E2F1 and E2F3 each associate
with the Bok promoter in vivo, in agreement with the aforementioned luciferase result.
The fact that immunoprecipitation with a control antibody (anti-IgG) results in absence of
signal from the Bok promoter, demonstrates the specificity of the interaction between
E2Fs and the Bok promoter. In addition, the lower panel in Fig. 12 reveals that the
murine albumin promoter, which does not possess E2F sites and has been shown not to
associate with E2F (98), is not immunoprecipitated with E2F antibodies under identical
conditions.
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Figure 12. E2F1 and E2F3 associate with the Bok promoter in vivo.
Asynchronously growing NIH 3T3 were subject to chromatin
immunoprecipitation analysis with antibodies against E2F1 (lane 4),
E2F3 (lane 5), or IgG (lane 6). Following DNA purification, samples
were subject to PCR with primers designed to amplify the Bok promoter
or the albumin promoter as control.
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Chapter 3: Functional Relevance of Bok
In chapter two we demonstrate that E2F1 binds to the Bok promoter and leads to
its transcriptional activation. Since E2F1 is the most potent inducer of apoptosis amongst
the E2F family, it was interesting to see that other members of this family also regulate
the Bok promoter. Furthermore, the observation that Bok mRNA increases after serum
stimulation and that the Bok promoter is cell cycle regulated, suggested to us that Bok
might have an unprecedented role in cell cycle. In this chapter we will investigate the role
of Bok in cell cycle, E2F1-induced apoptosis and stress-induced apoptosis. We will use
RNA interference to deplete cells from Bok and test its effect in the aforementioned
context

Bok d-siRNA Shuts Down the Expression of Bok.
To determine the functional effect of increased Bok expression, we created H1299
cells lines that constitutively express a Flag epitope-tagged version of Bok. Expression of
the introduced Flag-Bok transgene was confirmed via RT-PCR and Western blot (Fig.
13A and 13B). Surprisingly, constitutive expression of Flag-Bok did not necessarily
induce spontaneous apoptosis in these cells, and several lines were developed. Clone #8
expressed the highest level of Flag-Bok and was this used for subsequent experiments.
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Figure 13. Stable over-expression of Flag-Bok protein. Flag-Bok
expressing H1299 cell lines were generated by transfection with
pcDNA3-Flag-Bok followed by selection with G418 (see Methods).
G418-resistant colonies emerged with same efficiency as control
pcDNA3. Of the first six lines emerging from this screen three expressed
Flag-Bok as measured by anti-Flag Western blot. Clone #8 was used for
subsequent experiments.
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In order to block Bok expression we decided to turn to RNAi, and we utilize an
approach that would target the most of the Bok mRNA. Using plasmid pcDNA3 FlagBok as template, we PCR amplified a 561 bp fragment of Bok and that PCR product
cloned it into pCRII-TOPO vector. We then transformed this plasmid into bacteria, grew
it up and screened for insert orientation. We finally identified one plasmid with each
orientation. Using a RiboMaxTM Large Scale RNA production System under the T7
promoter we in vitro transcribed and produced milligram quantities of RNA from both,
the sense and the antisense strand of Bok. We then continue and combine 60 µg of each
RNA strand and let them anneal by heating up to 65˚C and letting it slowly cool down to
room temperature. As control we ran an aliquot on a 4% agarose gel to make sure the
RNAs anneal and form a single band ~561 bp (not shown). After annealing we performed
the Dicer reaction (Block ITTM Dicer kit from Invitrogen) followed by purification. With
this experiment we generated a pool of ~21 bp diced-small interfering RNA (d-siRNA)
(Figure 14, lanes 2 and 3) directed to many different parts of the of the Bok mRNA
transcript. We then tested if these Bok d-siRNAs shut down the expression of Bok on
H1299 cell lines that constitutively express Bok (Flag-Bok). Figure 15 shows Western
blot analysis against Flag Bok protein after transfection of Bok d-siRNA at 24, 48 and 72
hours post transfection.

Bok is Not Necessary for E2F1-Induced Apoptosis.
We have shown that E2F1 overexpression increases Bok mRNA (Fig 4). For this
reason we hypothesize that Bok is down stream of E2F1 and being a pro-apoptotic
member of the Bcl-2 family it might be an important player in E2F1-induce apoptosis. In
36

1

2

3

50 bp
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Figure 14. Generation of Bok d-siRNA. Bok d-siRNA was produced by
in vitro transcription of the sense and anti-sense strand of Bok cDNA.
The product was then purified, mixed and heated to 65° followed by slow
cool down in order to anneal both ssRNA. The 561 bp dsRNA was then
diced using Invitrogen’s Dicer enzyme kit. This generated a pool of 2123 bp dsRNAi that was visualized in a 4% agarose gel after the reaction
(lane 2) and after purification (lane 3). Lane 1 is a 50bp ladder for size
comparison.
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Bok d-siRNA 72 hr

GFP 72 hr

Bok d-siRNA 48 hr

GFP 48 hr

Bok d-siRNA 24 hr

GFP 24 hr

Flag- Bok
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Figure 15. Bok d-siRNA shuts down the expression of Bok. H1299
Flag-Bok cell line were mock transfected with GFP or transfected with
Bok d-siRNA at 0 and 24 hrs. Cells were harvested at the indicated times
and 100 µg of cell lysate was run on a 12 % SDS-PAGE. Western blot
was against Flag-Bok and actin as a control.

38

B. ER-E2F1 + OHT

A. ER-E2F1 - OHT

Cell number

M1

M1

Sub G1 = 0.83%

Sub G1 = 20.27%

C. ER-E2F1 – OHT + Bok d-siRNA

M1

Sub G1 = 2.87%

D. ER-E2F1 + OHT + Bok d-siRNA

M1

PI staining

Sub G1 = 19.86%

Figure 16. Bok deficiency does not block E2F1-induced apoptosis.
This experiment was done in H1299 cells that stably express ER-E2F1
fusion protein. A. Mock transfected. B. Mock transfected and treated
with OHT. C. Transfected with Bok d-siRNA. D. Transfected with Bok
d-siRNA and treated with OHT. Note that there is no difference between
B. and D. therefore Bok is not necessary for E2F1 induced apoptosis.
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order to test this hypothesis, we used a cell line that stably expresses ER-E2F1 fusion
protein. When these cells are treated with 4-Hydroxytamoxifen (OHT) they undergo
apoptosis induced by E2F1 following its nuclear re-localization. Cells were mock
transfected or transfected with Bok d-siRNA and after 24, 48 and 72 hrs post-transfection
they were harvested, fixed with 70 % ethanol-PBS, stained with PI and sub-G1 content
measured by FACS analysis. We expected that cells lacking Bok by virtue of Bok dsiRNA would be more resistant to E2F1-induce apoptosis. Surprisingly Bok deficient
cells were not significantly resistant to the induction of apoptosis by E2F1 (Figure 16).
This suggests that Bok is not an essential player in the induction of apoptosis by E2F1, at
least in the limited context of our experimental model.

Bok is Not Necessary for Cell Cycle Progression.
We were very surprised by the observation that Bok message is up regulated by
E2F1 as well as by serum, since Bok is an apoptotic protein. However, this pattern of
regulation suggested that Bok plays a role in cell cycle control. The idea that Bcl-2 family
members regulate cell cycle progression is not new since there have been reports that
Bcl-2 negatively regulates cell cycle progression by increasing the activity of p27Kip1 135,
which leads to the formation of a repressive E2F4/p130 complex that in turn block cell
cycle progression through the G1/S boundary.

To determine if transient Bok deficiency would affect cell cycle progression,
H1299 cells were transiently transfected with Bok RNAi and cell cycle distribution was
determined. Since endogenous Bok is difficult to detect with current antibodies it was
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Figure 17. Bok is not required for cell cycle progression. The pattern
of Bok regulation suggested that Bok might have an important role in the
progression of cell cycle. However, neither over-expression nor depletion
of Bok significantly affected the cell cycle compared to control
counterparts. Experiment was performed more than three times and
representative data is shown. p values were more than 0.05.
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necessary to use a surrogate cell line to demonstrate that the Bok RNAi was functional.
Having established that the Bok RNAi was active (Fig 15), the parental H1299 cell line
was transfected with the Bok siRNA and cell cycle distribution was measured. Figure 17
shows a cell cycle analysis of cells that were mock transfected with pcDNA3-empty
vector, transfected with Flag-Bok plasmid, control RNAi or Bok d-siRNA. After
repeating this experiment several times we did not find any significant evidence that Bok
is required for cell cycle progression.

Bok Localizes to the Cytoplasm
The mechanism by which the Bcl-2 family of proteins induce cell death is not
completely understood, yet a key component is the activation of caspases. The Bcl-2
family of proteins regulate the activation of caspases by controling the release of
cytochrome C from the mitochondria; which with Apaf-1 and procaspase 9 form the
apoptosome. In the traditional view, pro- and anti-apoptotic members of the Bcl-2 family
are found as heterodimeric proteins in the cytosol. After stress such as DNA damage, proapoptotic proteins such as Bok, Bax, and Bak, release anti-apoptotic members and
oligomerizes or heterodimerizes with other pro-apoptotic members in the mitochondrial
membrane. It is propose that the pro-apoptotic proteins form “pores” in the mitochondrial
membrane bringing about the release of cytochrome C, and this event triggers the
apoptosis cascade.

In the traditional view Bok should be cytosolic, however a recent report from
Bartholomeusz et al. 4 suggests that Bok contains a nuclear export sequence (NES)
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H1299
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GFP-Bok

Merge

siControl

Bok d-si

Figure 18. Bok localizes to the cytoplasm. H1299 cells were cotransfected with GFP-Bok and either Bok d-siRNA or control RNA and
cell were then visualized by fluorescent microscopy. Over-expression of
GFP-Bok demonstrate that Bok is mainly cytoplasmic. Top row,
separation from blue (DAPI) and green (GFP-Bok). As expected cotransfection with Bok d-siRNA abrogated the expression of Bok.
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and is also found in the nucleus, where its apoptotic activity is enhanced. In order to
determine where does Bok localizes we turned to fluorescent microscopy using a green
fluorescent protein (GFP) tagged Bok construct. H1299 cells were co-transfected with
GFP-Bok and either Bok d-siRNA or siControl using lipofectamine reagent and observed
under the fluorescent microscope after 24 hrs. Figure 18 demonstrates that GFP-Bok
localizes primarily to the cytoplasm. Thus, in our hands nuclear Bok appears minimal.

In order to determine if Bok’s apoptotic activity is enhanced in the nucleus we
developed H1299 cells that stably express an HA tagged- estrogen receptor (ER) taggedfusion of Bok (Fig 19A). Western blot against HA reveal that all three cell lines express
HA-ER-Bok fusion protein, however cell line number 2 less strong. Figure 19B
demonstrate that HA-ER-Bok fusion protein is express in the cytoplasm and after
treatment with the ER ligand, OHT, the fusion protein is forced into the nucleus, however
some stays in the cytoplasm. Using this experimental approach H1299 HA-ER-Bok cell
lines were treated with or without 300nM OHT and analyzed by FACS for subG1-DNA
content as a measure of apoptosis. In contrast to reports this did not induce any
spontaneous apoptosis at 48 or 72 hrs (Fig 20 lanes 2, 6 and 10). We also performed a
similar experiment where H1299 HA-ER-Bok cell line was treated with and without
OHT and also 200nM Flavopiridol, since H1299 cells undergo apoptosis after FP
treatment (86). Consistent with our previews result this did not enhance Bok’s apoptotic
activity. If observed carefully, shuttling Bok into the nucleus slightly decreased sub-G1
DNA content (Fig 20, compare lanes 3 and 4, 11 and 12) suggesting that Bok’s apoptotic
role is in the cytoplasm. Similar results were seen in an additional experiment; however,
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Figure 19. Generation of responsive H1299 HA-ER-Bok cell line.
HA-ER-Bok expressing H1299 cell lines were generated by transfection
with pcDNA3-HA-ER-Bok followed by selection with G418 (see
Methods). (A) At least three cell lines emerging from this screen
expressed HA-ER-Bok as measured by anti-HA Western blot. (B)
Fractionatio experiment reveal that ER-Bok is expressed in the cytoplasm
and after treatment with 300 nM OHT more than half of ER-Bok is
shuttled into the nucleus.
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Figure 20. Bok’s apoptotic role is not enhanced in the nucleus. H1299
HA-ER-Bok cell lines1, 2 and 4 were treated with or without 300 nM
OHT in order to shuttle Bok into the nucleus. In contrast to reports this
did not induce any spontaneous apoptosis as measured by FACS for subG1 DNA content, after 48 and 72 hrs of OHT treatment (compare lane 1
and 2, 5 and 6, 9 and 10). We also combined OHT and flavopiridol
treatment (to induce apoptosis) and tested if Bok in the nucleus had an
enhance apoptotic activity, however we saw a slightly opposite effect
(compare lanes 3 and 4, 7 and 8, 11and 12). Experiment was performed
twice in singles each. Representative result is shown.
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+FP

further experimentation in duplicates or triplicates is needed to solidify this observation.
Additionally this experiment is limited by the lack of good antibody against endogenous
Bok, since tagging Bok with GFP or HA-ER might affect the ability of Bok to move to
different compartments in the cell.

Bok Expression Sensitizes Cells to Stress-Induced Apoptosis
The Flag-Bok expressing cells generated in Figure 13 grew at the same rate as
parental H1299s (Fig 21). In light of the observation that Bok over-expression alone is
not sufficient for apoptosis induction, we sought to determine whether over-expression of
Bok sensitizes cells to stress-induced apoptosis. To this end, the H1299-Flag-Bok #8 cell
line (as well as parental H1299s) were assayed for viability after treatment with the
cyclin-dependent kinase inhibitor flavopiridol, which we have previously shown to
induce apoptosis in H1299 cells 86,88. Fig. 21 reveals that flavopiridol-induced loss of
viability is greatly accelerated in Bok expressing cells.

We next sought to verify our viability assay in a more direct measurement of
apoptosis induction. The H1299–Flag-Bok cell line and control H1299s were treated with
flavopiridol, harvested at 24 hrs intervals, stained with propidium iodide (PI) and assayed
for sub-G1 DNA content via flow cytometry. In agreement with low viability, there was a
significant increase in sub-G1 content within the flavopiridol treated H1299-Flag-Bok
cell lines in comparison to the parental controls (Fig. 21). Similar results were obtained
with other genotoxic agents (Fig 22). For further confirmation, we conducted Western
blot analysis for the presence of poly-ADP ribose polymerase (PARP) cleavage (a
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measurement of apoptosis) within the same experiment. As expected, both H1299-FlagBok and parental H1299s displayed cleavage of PARP, however, PARP cleavage began
24 hrs post flavopiridol treatment and was maximal at 48 hrs in the Bok expressing cell
line, whereas PARP cleavage was noticeable 48 hrs and maximal at 72 hrs within the
H1299 parental controls (Fig. 23). Taken together, these data suggest that expression of
Bok sensitizes cells to rapid apoptosis induction.
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Figure 21. Kinetics of apoptosis induction in response to Flavopiridol
treatment. H1299 and H1299 Flag-Bok cell line #8 were plated in 60mm plates and their growth rate/survival was measured by trypsinization,
followed by counting trypan blue excluding cells after treatment with
DMSO control or flavopiridol [200 nM]. H1299 and H1299 Flag-Bok
cell lines grow at similar rates (circles and squares), however upon
treatment with FP, the Flag Bok cell line dies faster. Experiment was
performed in triplicates and p values were less than 0.05.
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Figure 23. A molecular marker of apoptosis is seen by 24 hr after FP
treatment in the Flag-Bok expressing cell line. Protein extracts of
H1299 or H1299 Flag-Bok cell lines after treatment of flavopiridol were
harvested in 24 hr intervals and Western blotted for PARP as a measure
of apoptosis. PARP cleavage was visible by 24 hrs and maximal at 48 hrs
on H1299 Flag Bok cell line in contrast to being maximal at 72hrs on
parental H1299 cells
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Chapter 4: Discussion

In the current work we show that the Bok promoter is activated by serum addition
in a manner dependent upon a conserved E2F site in the promoter. The Bok promoter is
also activated by over-expression of S phase promoting members of the E2F family. We
also show by ChIP assay that E2F1 and E2F3 both bind the Bok promoter region in vivo.
Finally we find that Bok over-expression sensitizes to flavopiridol-induced apoptosis.

Our understanding of the interactions between the E2F and Bcl-2 families of
proteins that modulate survival are growing increasingly complex and interwoven. This
is the first example of a pro-apoptotic member of the Bcl-2 family found to have its
expression tied to cell cycle progression, although this is no t the first example of
regulation of Bcl-2 family by E2F1 in its apoptotic role. It has been known for some time
that E2F1 can repress the expression of Bcl-2 25 and, we have demonstrated that E2F1
can directly repress the Mcl-1 promoter 19,87. Other laboratories have found that several
pro-apoptotic BH3-only members of the Bcl-2 family (PUMA, Noxa, Bim, and Hrk/DP5)
are also activated by E2F1 46. In the current work, we find that E2F1 can directly activate
expression of Bok. Since E2F1 is a well-characterized inducer of apoptosis its effects on
Mcl-1, PUMA, Noxa, Bim, Hrk/DP5 and Bok are logical. The net consequence of overactive E2F1 is thus to tip the balancing act within the Bcl-2 family toward apoptosis.
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The transcriptional activation of Bok at the G1/S boundary by serum stimulation
was not anticipated since Bok is considered a pro-apoptotic member of the Bcl-2 family.
Bok might have a number of roles at G1/S. Bok might serve a specific G1/S or S phase
function. For example, recent work has shown that BID (a pro-apoptotic Bcl-2 protein)
can induce an S phase arrest following its phosphorylation by ATM 35,70,152. While we
cannot formally exclude the possibility that Bok has a specific G1/S function, we have
performed extensive siRNA and shRNAi experimentation aimed at depleted proliferating
cells of Bok. Though we are confident in our ability to deplete cells of 80-90% of
endogenous Bok mRNA or exogenous protein, we obtained no convincing evidence that
Bok deficiency affects cell cycle progression. Of course these studies are hampered by
the lack of good quality antibody to Bok, and so, it is possible that future studies will find
an additional role for Bok in cell cycle.

An alternative role for Bok induction at the G1/S boundary would be to serve as a
checkpoint. G1/S phase cells are known to be highly sensitive to apoptosis induction and
it reasonable that expression of Bok might mediate this sensitivity, at least in part. This
model would lead to the prediction that cells expressing exogenous Bok would survive
and grow normally, but would be sensitive to apoptosis-inducing stresses. Indeed, this
appears to be the case since Flag-Bok expressing H1299 cell lines are obtained with high
efficiency and they grow normally, yet they are much more readily killed by treatment
with flavopiridol, as well as by other death-inducing agents. Taken together the results in
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this dissertation demonstrate that Bok is a cell cycle regulated member of the Bcl-2
family that serves as a checkpoint sensitizing replicating cells to stress-induced apoptosis.

Future Studies
Throughout my graduate studies, we have demonstrated that Bok mRNA is
upregulated by serum stimulation and by E2F1 over-expression. We have also cloned and
characterized the Bok promoter and demonstrated that E2F1 directly binds and
transactivates it via a conserved E2F element. In addition we have shown that high
expression of Bok sensitizes cells to apoptosis after treatment with chemotherapeutric
agents. Furthermore, it is known that appropriate patterns of apoptosis are essential for
normal tissue development, and since Bok is an inducer of apoptosis and it is expressed at
various levels in diverse tissues 126, it may play a significant role in mouse development..
To test these hypotheses future experiments should use the reagents we have developed
to generate Bok-deficient mice using the conventional targeting approach.

Bok mRNA expression is highest in the uterus, ovaries and testes; therefore these
tissues are most likely to be dramatically affected by Bok deficiency. However, we may
also expect to see tumor suppressor effects in other tissue that express Bok including
lung, brain, liver, mammary epithelium and lymphoid tissues. Assuming that Bok
heterozygous mice are viable and fertile, we expect them to be developmentally normal,
however litter sizes and animal weights will be monitored and recorded to detect any
differences from control animals. Mice will be observed carefully for overall health and
behavior in aspects such as appearance, viability, growth rate, fertility and longevity. Any
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outstanding abnormalities will be noted and affected animals euthanized. Organs from
age matched wt and heterozygous animals will be removed, examined for gross
abnormalities and weighed to determine if Bok deficiency affects organ size. The organs
we are particularly interested include the testes, ovaries, uterus, lung, brain, liver and
lymph nodes. Once weighed, organs will be fixed, paraffin-embedded and sectioned for
histological examination and immunohistochemistry for BrdU, TUNEL and levels of Bok
protein.

Two heterozygous mice will be crossed and by Mendelian genetics we expect that
about twenty-five percent of the offspring to be homozygous null. The first question that
this analysis will answer is whether we can establish Bok-deficient mice. Since Bok is an
apoptotic protein we predict that Bok-deficient mice will display apoptotic defects in
multiple tissues. The defects we may observe could be organ enlargement, but perhaps
poor organization and differentiation due to impaired apoptosis. Assays such as TUNEL
and apo-BrdU would reveal fewer positive cells compared to wild type counter parts. For
example, mice over-expressing Bcl-2 in the ovaries results in suppression of follicular
cell apoptosis, enhancement of folliculogenesis and increased germ cell tumorigenesis 56.
Interestingly, the Bcl-2 transgenic mice were fertile and their litters were on average 2
pups larger than litters of wild-type females, due to enhanced folliculogenesis. We think
that it is likely that the effects of Bok deficiency, at least within the ovary, will be similar
to the effects of Bcl-2 over-expression, and thus, Bok deficient animals will probably be
more fertile than control mice. Again, health and behavior will be monitored for up to
twenty-four months to determine these animals develop spontaneous tumors.
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In the case of successfully developing Bok-deficient mice, we could cross these
animals with commercially available Bax- and Bak-deficient animals in order to identify
unique versus redundant or cooperative functions within this family of proteins. If viable,
we anticipate that pathological effects of either Bax or Bak deficiency may be
significantly aggravated by deficiency of Bok, particularly in lymphoid or reproductive
tissue where the Bcl-2 family members are co-expressed at high levels. In addition,
combined deficiencies may result in a stronger predisposition toward tumor formation.

In summary, future studies with a Bok-deficient animal will seek to determine the
role of Bok in vivo and in mouse tumorgenesis. We anticipate that Bok will be found to
be a tumor suppressor and that Bok-deficient animals will be predisposed to hyperplasia
and neoplasia. We also anticipate that Bok may play a role in reproductive development
or physiology.
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